- Home
- CTRN vs FBIOP Comparison
CTRN vs FBIOP Comparison
Compare CTRN & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- FBIOP
- Stock Information
- Founded
- CTRN 1946
- FBIOP N/A
- Country
- CTRN United States
- FBIOP United States
- Employees
- CTRN N/A
- FBIOP 101
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- FBIOP Biotechnology: Pharmaceutical Preparations
- Sector
- CTRN Consumer Discretionary
- FBIOP Health Care
- Exchange
- CTRN Nasdaq
- FBIOP Nasdaq
- Market Cap
- CTRN N/A
- FBIOP N/A
- IPO Year
- CTRN 2005
- FBIOP N/A
- Fundamental
- Price
- CTRN $20.83
- FBIOP $6.74
- Analyst Decision
- CTRN Strong Buy
- FBIOP
- Analyst Count
- CTRN 3
- FBIOP 0
- Target Price
- CTRN $28.00
- FBIOP N/A
- AVG Volume (30 Days)
- CTRN 79.1K
- FBIOP N/A
- Earning Date
- CTRN 06-03-2025
- FBIOP N/A
- Dividend Yield
- CTRN N/A
- FBIOP N/A
- EPS Growth
- CTRN N/A
- FBIOP N/A
- EPS
- CTRN N/A
- FBIOP N/A
- Revenue
- CTRN $753,079,000.00
- FBIOP N/A
- Revenue This Year
- CTRN $5.91
- FBIOP N/A
- Revenue Next Year
- CTRN $4.59
- FBIOP N/A
- P/E Ratio
- CTRN N/A
- FBIOP N/A
- Revenue Growth
- CTRN 0.69
- FBIOP N/A
- 52 Week Low
- CTRN $13.66
- FBIOP N/A
- 52 Week High
- CTRN $29.41
- FBIOP N/A
- Technical
- Relative Strength Index (RSI)
- CTRN 50.69
- FBIOP 67.87
- Support Level
- CTRN $19.12
- FBIOP $6.00
- Resistance Level
- CTRN $21.01
- FBIOP $6.80
- Average True Range (ATR)
- CTRN 1.58
- FBIOP 0.42
- MACD
- CTRN 0.21
- FBIOP 0.16
- Stochastic Oscillator
- CTRN 86.24
- FBIOP 96.19
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.